Cancer gene therapy developer aims for $60M IPO; Nanowafers as an alternative to eye drops?;

> Cancer gene therapy developer MultiVir aims to raise $60 million via Nasdaq IPO that is supposed to commence during the week of May 4. More

> Contract manufacturer Recipharm agreed to produce LIDDS' phase II Liproca Depot, a reformulated candidate to treat prostate cancer via local administration. More

> Researchers at Baylor College Medicine are working on the use of drug delivering nanowafers as an alternative to eye drops. More

> New York City's Anterios--the developer of a lotion containing the active ingredient of Botox (marketed by recently acquired Allergan) that can be applied on the skin via a 10-minute massage--plans to raise $51 million via Nasdaq IPO. Earlier this month, it filed with the SEC to raise $58 million. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.